Merck rebounds to win a milestone immunotherapy approval in early breast cancer

The Food and Drug Administration has made Merck & Co.'s Keytruda the first immunotherapy available for patients with a form of early-stage breast cancer, reversing an earlier decision to reject the treatment now that the drugmaker has accrued new data to support its use.